Metabolomics Studies in Type 2 Diabetes and Insulin Resistance: A Short Review

Background: Type 2 diabetes is a heterogeneous metabolic disorder primarily characterized by insulin resistance and impaired pancreatic beta-cell function. Conventional diagnostic approaches are unable to identify early metabolic alterations occurring in the preclinical stages of the disease. This review article was designed with the aim of synthesizing key findings from metabolomics studies in type 2 diabetes and insulin resistance. Methods: This article is a short narrative review that, based on a search of credible scientific sources, analyzes findings related to key metabolites—including amino acids (particularly branched-chain, aromatic, and glycine), lipids (ceramides and triacylglycerols), organic acids, bile acids, and gut microbiome-derived metabolites. Results: Evidence indicates that elevated levels of branched-chain and aromatic amino acids, reduced glycine, accumulation of toxic lipids (such as ceramides), disrupted bile acid metabolism, and gut microbial dysbiosis are strongly associated with the risk of type 2 diabetes. Together with low-grade chronic inflammation, these factors provide an integrated picture of the multifactorial pathophysiology of type 2 diabetes. Conclusion: Metabolomics not only enables the identification of predictive biomarkers but also lays the groundwork for developing targeted therapeutic interventions and precision medicine in type 2 diabetes.